Valneva’s (VALN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Valneva (NASDAQ:VALN) in a report published on Tuesday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Separately, Guggenheim reduced their price target on shares of Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, March 24th.

Valneva Price Performance

VALN opened at $6.79 on Tuesday. The company has a fifty day moving average price of $6.99 and a two-hundred day moving average price of $5.65. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm has a market capitalization of $551.76 million, a PE ratio of -52.23 and a beta of 1.85. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50.

Valneva (NASDAQ:VALN) last issued its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, analysts anticipate that Valneva will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

Large investors have recently made changes to their positions in the stock. ABC Arbitrage SA acquired a new position in Valneva in the 4th quarter worth $84,000. GAMMA Investing LLC bought a new position in shares of Valneva during the first quarter worth about $94,000. Finally, Wells Fargo & Company MN raised its position in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after buying an additional 30,859 shares during the last quarter. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.